In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Regeneron Pharmaceuticals displays a significant implied upside of 85.8%, supported by a high-confidence fair value above $1,400 versus the current price near $755. Robust financial health and Monte Carlo median valuation ($1,640) indicate strong growth potential amid moderate downside risk (6.2%). However, high volatility (CV 104.94%) suggests considerable price swings.